Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $17.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective upped by HC Wainwright from $15.00 to $17.00 in a research report released on Monday, Marketbeat.com reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2027 earnings at $1.27 EPS, FY2028 earnings at $1.62 EPS and FY2029 earnings at $2.31 EPS.

Separately, Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ ETON opened at $12.01 on Monday. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $15.00. The company has a market cap of $312.87 million, a P/E ratio of -54.59 and a beta of 1.38. The business’s 50 day moving average is $11.57 and its two-hundred day moving average is $7.32.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ETON. Parkman Healthcare Partners LLC boosted its position in shares of Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after acquiring an additional 7,029 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eton Pharmaceuticals during the third quarter valued at approximately $54,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at approximately $90,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after buying an additional 32,365 shares during the period. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.